Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1984-11-15
|
pubmed:abstractText |
In a cross-sectional study, sera of 81 adult diabetic in-patients were tested for the presence of pancreatic islet cell antibodies (ICA), both IgG and complement-fixing. All patients had been well controlled initially with oral hypoglycaemic agents and therefore had been classified as having Type 2 (non-insulin-dependent) diabetes. However, 14 were subsequently classified as Type 1 (insulin-dependent) because they became insulin-dependent within 2 months of diagnosis. Ten of these patients (71%) were ICA-positive. Sixty-seven patients had been non-insulin-dependent for at least 1 year after diagnosis. Circulating ICA were present in 18 patients and 16 of these (89%) required insulin therapy. Secondary oral hypoglycaemic agent failure developed within a mean period of 3.7 years after diagnosis. In contrast, in the ICA-negative sub-group (n = 49) insulin treatment became necessary in 29 patients. Secondary oral hypoglycaemic agent failure of these patients had developed after a mean period of 8.4 years, which was significantly longer than in the ICA-positive patients (p less than 0.01). Complement-fixing-ICA were detected only in sera with an ICA-IgG titre of at least 8, and its prevalence was similar in the sub-groups tested, i.e., the Type 1 diabetic patients and the patients with secondary oral hypoglycaemic agent failure. With HLA-DR typing, a significant excess of the DR3 antigen and heterozygous DR3/DR4 phenotypes was found in ICA-positive patients with secondary oral hypoglycaemic agent failure and in the Type 1 diabetic patients, which was comparable with the frequencies reported in juvenile-onset Type 1 diabetes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Autoantibodies,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DR Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class II,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/islet cell antibody
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0012-186X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
27 Suppl
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
90-2
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:6383926-Adult,
pubmed-meshheading:6383926-Aged,
pubmed-meshheading:6383926-Antibodies,
pubmed-meshheading:6383926-Autoantibodies,
pubmed-meshheading:6383926-Diabetes Mellitus,
pubmed-meshheading:6383926-Diabetes Mellitus, Type 1,
pubmed-meshheading:6383926-Diabetes Mellitus, Type 2,
pubmed-meshheading:6383926-HLA-DR Antigens,
pubmed-meshheading:6383926-Histocompatibility Antigens Class II,
pubmed-meshheading:6383926-Humans,
pubmed-meshheading:6383926-Hypoglycemic Agents,
pubmed-meshheading:6383926-Islets of Langerhans,
pubmed-meshheading:6383926-Middle Aged,
pubmed-meshheading:6383926-Phenotype
|
pubmed:year |
1984
|
pubmed:articleTitle |
Correlation of islet cell antibodies and HLA-DR phenotypes with diabetes mellitus in adults.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|